GlassScriptPhysician profile
Emilie Wang
NPI 1417341637
$7,368.05
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2021: $1,338 · 2022: $4,140 · 2023: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.44 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $951.51 | 2021-2023 | |
| Pfizer INC. | $553.84 | 2019-2023 | |
| Seagen INC. | $470.21 | 2019-2023 | Adcetris, Padcev |
| Daiichi Sankyo INC. | $382.32 | 2021-2023 | Enhertu, Injectafer |
| Genentech USA, INC. | $358.54 | 2019-2023 | Perjeta, Phesgo, Rozlytrek |
| Janssen Biotech, INC. | $341.60 | 2022-2023 | Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $276.31 | 2021-2023 | Keytruda, Lenvima |
| Incyte Corporation | $269.93 | 2021-2023 | Jakafi, Monjuvi |
| Lilly USA, LLC | $253.25 | 2021-2023 | Jaypirca, Verzenio |
| Gilead Sciences, INC. | $242.83 | 2021-2023 | Trodelvy |
| Eisai INC. | $209.13 | 2021-2023 | |
| Celgene Corporation | $180.12 | 2022-2023 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $159.76 | 2021-2023 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $150.46 | 2021-2023 | Calquence |
| Regeneron Healthcare Solutions, INC. | $148.61 | 2022-2023 | Libtayo |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilie Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.